Dilution of Share Value Through Stock Acquisition Rights
First written in FY2019. 12 of 19 entries say "Materialised", first in FY2020-Q3. Latest entry: FY2026-H1.
The whole theme swung hardest in 2017: 37 of 68 companies on the "Worse" side.
- FY2026-H1MaterialisedAnnual report
「1 November 2025–31 December 2025 (Note) 1 7,200 19,827,162 741 1,428,888 741 1,338,888 (Note) 1. Increase due to the exercise of stock acquisition rights.」
During the interim accounting period, 7,200 shares were added to the total number of issued shares through the exercise of stock acquisition rights, resulting in actual share dilution. - FY2025WorsenedAnnual report
「As of the end of the consolidated fiscal year, the number of potential shares represented by the remaining unexercised stock acquisition rights was 281,500 shares, equivalent to 1.42% of the total 19,819,962 issued shares.」
The number of unexercised potential shares increased from 182,400 shares, or 0.92%, as of the previous disclosure date to 281,500 shares, or 1.42%. In addition to dilution from the exercise of stock acquisition rights, the disclosure also addresses the possibility of future grants and exercises. - FY2025-H1MaterialisedAnnual report
「1 November 2024–30 April 2025 (Note) 3,600 19,812,762 36 1,428,074 36 1,338,074 (Note) Increase due to the exercise of stock acquisition rights.」
During the interim accounting period, 3,600 shares were added to the total number of issued shares through the exercise of stock acquisition rights, and capital stock and the capital surplus each increased by ¥36,000. - FY2024-Q1MaterialisedAnnual report
「1 November 2023–31 January 2024 45,000 19,806,100 1,076 1,426,474 1,076 1,336,474 (Note) Increase due to the exercise of stock acquisition rights.」
During the first quarter, 45,000 shares were added to the total number of issued shares through the exercise of stock acquisition rights, and capital stock and the capital surplus each increased by ¥1.076 million. Dilution actually occurred. - FY2023MitigatedAnnual report
「As of the end of the fiscal year, the number of potential shares represented by the remaining unexercised stock acquisition rights was 182,400 shares, equivalent to 0.92% of the total 19,761,100 issued shares.」
The number of unexercised rights declined from 564,900 shares, or 3.0%, in the previous fiscal year to 182,400 shares, or 0.92%. Although dilution from the exercise of stock acquisition rights also occurred during the fiscal year, exposure to potential shares at year-end declined. - FY2023-Q3MaterialisedAnnual report
「1 May 2023–31 July 2023 (Note) 360,900 19,056,600 3,243 694,119 3,243 604,119 (Note) Increase due to the exercise of stock acquisition rights.」
During the third-quarter accounting period, 360,900 shares were added to the total number of issued shares through the exercise of stock acquisition rights, and capital stock and the capital surplus each increased by ¥3.243 million. Dilution has continued to occur in practice. - FY2023-Q1MaterialisedAnnual report
「Change in total issued shares 9,900 shares Change in capital stock ¥1.650 million Change in capital surplus ¥1.650 million (Note) Increase due to the exercise of stock acquisition rights.」
During the first quarter, 9,900 shares were added to the total number of issued shares through the exercise of stock acquisition rights, resulting in actual dilution. In addition, stock acquisition rights equivalent to 4,200 common shares were issued as the tenth series. - FY2022WorsenedAnnual report
「As of the end of the fiscal year, the number of potential shares represented by the remaining unexercised stock acquisition rights was 564,900 shares, equivalent to 3.0% of the total 18,685,800 issued shares.」
The number of unexercised rights increased from 208,700 shares in the previous fiscal year to 564,900 shares. Although their proportion of issued shares declined from 3.4% to 3.0%, the absolute number of potential shares increased. - FY2022-Q3MaterialisedAnnual report
「1 May 2022–31 July 2022 (Note) 13,500 18,684,900 8,326 688,503 8,326 598,503 (Note) Increase due to the exercise of stock acquisition rights.」
During the third-quarter accounting period, 13,500 shares were added to the total number of issued shares through the exercise of stock acquisition rights, and capital stock and the capital surplus each increased by ¥8.326 million. Dilution has continued to occur in practice. - FY2022-Q2MaterialisedAnnual report
「1 February 2022–30 April 2022 (Note) 18,000 18,671,400 828 680,177 828 590,177 (Note) Increase due to the exercise of stock acquisition rights.」
During the second-quarter accounting period, 18,000 shares were added to the total number of issued shares through the exercise of stock acquisition rights, and capital stock and the capital surplus each increased by ¥828,000. Dilution has continued to occur in practice. - FY2022-Q1MaterialisedAnnual report
「3. From 1 February 2022 to 28 February 2022, the exercise of stock acquisition rights increased the total number of issued shares by 5,400, capital stock by ¥556,000 and the capital surplus by ¥556,000.」
During the first quarter, the exercise of stock acquisition rights on 20 January 2022 also increased the number of issued shares by 27,000, and a further 5,400 rights were exercised after filing. Stock dilution from the exercise of stock acquisition rights has continued to occur in practice. - FY2021MaterialisedAnnual report
「As of the end of the fiscal year, the number of potential shares represented by the remaining unexercised stock acquisition rights was 208,700 shares, equivalent to 3.4% of the total 6,208,800 issued shares.」
During the fiscal year, 62,400 shares were issued through the exercise of stock acquisition rights, leaving 208,700 unexercised rights at year-end. The possibility of dilution from new grants and exercises of stock acquisition rights is also disclosed. - FY2021-Q3MaterialisedAnnual report
「1 May 2021–31 July 2021 (Note) 7,200 6,187,800 216 677,523 216 587,523 (Note) Increase due to the exercise of stock acquisition rights.」
During the third-quarter accounting period, 7,200 shares were added to the total number of issued shares through the exercise of stock acquisition rights, and capital stock and the capital surplus each increased by ¥216,000. The disclosure adds the fact that dilution from stock acquisition rights actually occurred. - FY2021-Q2MaterialisedAnnual report
「1 February 2021–30 April 2021 (Note) 18,600 6,180,600 4,067 677,307 4,067 587,307」
During the second-quarter accounting period, 18,600 shares were added to the total number of issued shares through the exercise of stock acquisition rights, and capital stock and the capital surplus each increased by ¥4.067 million. The disclosure records the actual occurrence of dilution from stock acquisition rights. - FY2021-Q1WorsenedAnnual report
「3. From 1 February 2021 to 28 February 2021, the exercise of stock acquisition rights increased the total number of issued shares by 7,800, capital stock by ¥1.570 million and the capital surplus by ¥1.570 million.」
During the first quarter, the number of issued shares increased by 15,600 through the exercise of stock acquisition rights, and new stock acquisition rights equivalent to 2,000 and 3,000 common shares were issued as the seventh and eighth series, respectively. The exercise of 7,800 stock acquisition rights was also disclosed after filing, adding further dilution exposure. - FY2020MitigatedAnnual report
「As of the end of the fiscal year ending October 2020, the number of potential shares represented by the remaining unexercised stock acquisition rights was 87,000 shares, equivalent to 4.2% of the total 2,048,800 issued shares.」
Although the number of potential shares declined from 141,600 shares, or 7.4%, in the fiscal year ending October 2019 to 87,000 shares, or 4.2%, the possibility of dilution from future grants and exercises of stock acquisition rights continues to be disclosed. - FY2020-Q3MaterialisedAnnual report
「1 May 2020–31 July 2020 (Note) 1 43,200 2,035,200 2,782 671,719 2,782 581,719」
During the third-quarter accounting period, 43,200 shares were added to the total number of issued shares through the exercise of stock acquisition rights, and capital stock and the capital surplus each increased by ¥2.782 million. The disclosure records the actual occurrence of dilution from stock acquisition rights. - FY2020-Q2WorsenedAnnual report
「The Company will issue stock acquisition rights free of charge to its employees and external collaborators in order to further increase their motivation and morale to improve the Company's performance. Number of stock acquisition rights to be issued: 34 (each stock acquisition right represents 100 common shares)」
As a subsequent event, the issuance of 34 stock acquisition rights, equivalent to 3,400 common shares, to employees and external collaborators was approved, adding exposure to potential shares. - FY2019First statedAnnual report
「As of the end of the fiscal year ending October 2019, the number of potential shares relating to these stock acquisition rights was 141,600 shares, equivalent to 7.4% of the total 1,920,000 issued shares.」
While granting stock acquisition rights as an incentive to secure personnel and increase long-term corporate value, the Company identifies dilution from their exercise as a risk.